Incyte Corporation operates as a biopharmaceutical company. The company engages in the discovery, development, and commercialization of proprietary therapeutics.
The company is focused in two therapeutic areas that are defined by the indications of…
Analysis
Hidden champion
Incyte Corporation fits the profile of a hidden champion, yet the market has not awarded it the premium its quality earns. Worth noting: the cash the business generates has lagged behind what the income statement shows.
On valuation, the picture is attractive. The owner-earnings multiple stands at 14.7×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around 2% a year, against analyst forecasts of 12%. The price, in other words, assumes less than the experts do.
Growth is moderate; the safety picture is sturdy. The company scores 20/20 on our value-creation score: strong value creator.
Flags to be aware of: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.
360° rank · history
1007550250
Feb 202697
92
2026
All-time high
97
Feb 2026
All-time low
65
Mar 2026
Average rank
85
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
87
—
—
—
Price/Earnings
7
—
—
—
Price/Book
50
—
—
—
Dividend Yield
—
—
—
—
Value (overall)
69
—
—
—
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.